Cell Therapeutics preclinical data

The Seattle company reported that CT-2576 and CT-3578 inhibited IL-2 signaling in T cells in animal models by regulating the breakdown of inositol phosphate-glycan (gly-PI).

CT-2576 did not block IL-2 release or induction, but blocked gamma interferon and IL-4 release. At submicromolar concentrations, it inhibited the proliferation of B cells stimulated with anti-IgM antibody and IL-4. It also induced specific T cell anergy in a mixed tumor lymphocyte culture. ...